Plain-English translation of NCT05955365 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial compares two different approaches to blood-thinning treatment for people with atrial fibrillation (irregular heartbeat) who need a heart stent. One group will take a (a type of blood thinner) for one month, then switch to a (direct-acting oral anticoagulant) for the remaining 11 months. The other group will follow the standard approach of taking multiple blood thinners together for the first month, then two for several more months. The study wants to see if the simpler approach works just as well while reducing bleeding risks.
People with atrial fibrillation who receive heart stents face a difficult balance: they need blood thinners to prevent clots and strokes, but too many blood thinners at once increase the risk of serious bleeding. This trial exists to find out if a simpler, shorter medication plan can keep people safe while reducing this bleeding risk.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either the simplified medication plan or the standard plan and followed for 12 months. If you receive the simplified approach, you'll take one blood-thinning pill for the first month, then switch to a different blood thinner for the remaining 11 months. If you receive the standard approach, you'll take multiple blood thinners together initially, then adjust them over time. Throughout the year, you'll have follow-up visits to monitor how well the treatment is working and check for any side effects or bleeding problems.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Belgium
France
Germany
Italy